An update on the use of ophthalmic ketorolac tromethamine 0.4%

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 1, 2006, Pages 99-107

  Perry, Henry D ^a   Donnenfeld, Eric D ^a,b,c  

^a OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^b Manhattan Eye and Ear Infirmary   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Cystoid macular oedema; Ketorolac tromethamine; Miosis

Indexed keywords

ACULAR LS; ALKANOIC ACID; ARACHIDONIC ACID; ARYLACETIC ACID DERIVATIVE; BROMFENAC; CHLORAMPHENICOL; CORTICOSTEROID DERIVATIVE; CYCLOPENTOLATE; CYCLOPLEGIC AGENT; CYCLOSPORIN A; DICLOFENAC; ERYTHROMYCIN; EYE DROPS; FLURBIPROFEN; INDOLE DERIVATIVE; INDOMETACIN; KETOROLAC TROMETAMOL; LEUKOTRIENE; LOTEPREDNOL ETABONATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLACETIC ACID DERIVATIVE; PHOSPHOLIPASE A2; PLACEBO; POLYMYXIN B; PREDNISOLONE; PREDNISOLONE ACETATE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; RIMEXOLONE; SUPROFEN; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; BURN; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CORNEA DISEASE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EYE INFLAMMATION; EYE PAIN; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MIOSIS; MONOTHERAPY; NONHUMAN; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN SYNTHESIS INHIBITION; REFRACTIVE SURGERY; RETINA MACULA CYSTOID EDEMA; SUBCAPSULAR CATARACT; TREATMENT INDICATION; VISUAL FIELD DEFECT;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EYE DISEASES; HUMANS; KETOROLAC TROMETHAMINE; PROSTAGLANDINS; UVEITIS, ANTERIOR;

EID: 30344481336     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.1.99     Document Type: Article

References (39)

1. MCCOLGIN AZ, HEIER JS: Control of intraocular inflammation associated with cataract surgery. Curr. Opin. Ophthalmol. (2000) 11:3-6.
2. POLANSKY JR, WEINREB RN: Steroids as anti-inflammatory agents. In: Pharmacology of the Eye. Sears ML (Ed.), Springer-Verlag, New York (1984):460-538.
3. QUINN CJ: Cystoid macular edema. Optom. Clin. (1996) 5(1):111-130.
4. ROBERTS CW: Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology (1996) 103:636-639.
5. RAY S, D'AMICO DJ: Pseudophakic macular edema. Semin. Ophthalmol. (2002) 17:167-180.
6. URSELL PG, SPALTON DJ, WHITCUP SM, NUSSENBLATT RB: Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J. Cataract Refract. Surg. (1999) 25(11):1492-1497.
7. MENTES J, ERAKGUN T, AFRASHI F, KERCI G: Incidence of cystoid macular edema after uncomplicated phacoemulsification. Ophthalmologica (2003) 217(6):408-412.
8. DONNENFELD ED, PERRY HD, WITTPENN J, SOLOMON R, CHOU T: Dose-response curve of a topical NSAID as a surgical tool before cataract surgery. Presented at The Annual American Society of Cataract and Refractive Surgery. Washington, DC, USA (2005):38948.
9. GUZEK JP, HOLM M, COTTER JB et al.: Risk factors for intraoperative complications in 1000 extracapsular cataract cases. Ophthalmology (1987) 94:461-466.
10. STEWART R, GROSSERODE R, CHEETHAM JK et al.: Efficacy and profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin. Ther. (1999) 21:723-732.
11. MCGHEE CN, DEAN S, DANESH-MEYER H: Locally administered ocular corticosteroids: benefits and risks. Drug Saf (2002) 25:33-55.
12. O'BRIEN TP: Emerging guidelines for rise of NSAID therapy to optimize cataract surgery patient care. Curr. Med. Res. Opin. (2005) 21(7):1131-1138.
13. WATERBURY LD, FLACH AJ: Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation. J. Ocul. Pharmacol. Ther. (2004) 20:345-352.
14. SOLOMON KD, DONNENFELD ED, RAIZMAN M et al.: Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J. Cataract Refract. Surg. (2004) 30(8):1653-1660.
15. BUCCI FA, EVANS RE, AMICO LM: Comparison of ketorolac 0.5%, ketorolac 0.4%, and diclofenac 0.1% - combined with prednisolone 0.1% on aqueous flare following cataract surgery. Presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2005):789.
16. EVANS RE, BUCCI FA, AMICO LM JR: Efficacy of ketorolac 0.5% versus ketorolac 0.4% following cataract surgery. Presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2005):790.
17. SANDOVAL HP, FERNANDEZ DE CASTRO LE, VROMAN DT, SOLOMON KD: Comparison of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution to prevent inflammation after phacoemulsification and intraocular lens implantation: a prospective, randomized, double-masked, clinical trial. Presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2005):796.
18. PRICE MO, PRICE FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr. Med. Res. Opin. (2004) 20(12):2015-2019.
19. PRICE FW JR, PRICE MO, ZEH W DOBBINS K: Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial. J. Refract. Surg. (2002) 18(2):140-144.
20. HIRNEISS C, NEUBAUER AS, KAMPIK A, SCHONFELD CL: Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction. A prospective, randomized, double-masked study. Graefes Arch. Clin. Exp. Ophthalmol. (2005) Mar 9 [Epub ahead of print]
21. HOLZER MP, SOLOMON KD, SANDOVAL HP, VROMAN DT: Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J. Cataract Refract. Surg. (2002) 28:93-99.
22. SOLOMON KD, VROMAN DT, BARKER D, GEHLKEN J: Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to controlinflammation after cataract extraction. Prospective randomized double-masked study. J. Cataract Refract. Surg. (2001) 27(8):1232-1237.
23. RHO DS: Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J. Cataract Refract. Surg. (2003) 29(12):2378-2384.
24. SRINIVASAN R, MADHAVARANGA: Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery. J. Cataract Refract. Surg. (2002) 28(3):517-520.
25. SNYDER RW, SIEKERT RW, SCHWIEGERLING J, DONNENFELD E, THOMPSON P: Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J. Cataract Refract. Surg. (2000) 26:1225-1227.
26. SOLOMON KD, TURKALJ JW, WHITESIDE SB, STEWART JA, APPLE DJ: Topical 0.5% ketorolac versus 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch. Ophthalmol. (1997) 115(9):1119-1122.
27. GOYAL R, SHANKAR J, FONE DL, HUGHES DS: Randomised controlled trial of ketorolac in the management of corneal abrasions. Acta Ophthalmol. Scand. (2001) 79(2):177-179.
28. RHO DS, SOLL SM: Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2004):2030.
29. HEIER JS, TOPPING TM, BAUMANN W, DIRKS MS, CHERN S: Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology (2000) 107:2034-2038; discussion 2039.
30. ARSHINOFF S, D'ADDARIO D, SADLER C, BILOTTA R, JOHNSON TM: Use of topical nonsteroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy. J. Cataract Refract. Surg. (1994) 20:216-222.
31. SCHECHTER BA, WITTPENN JR: Evaluation of ketorolac (acular ls) during the induction phase of cyclosporine a (restasis) therapy to improve patient comfort. Presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2005):2033.
32. KAISER PK, PINEDA R II: A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group. Ophthalmology (1997) 104:1353-1359.
33. FLACH AJ, STEGMAN RC, GRAHAM J, KRUGER LP: Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology (1990) 97:1253-1258.
34. ROBERTS CW: NSAID to decrease postoperative macular edema. Presented at The Annual American Society of Cataract and Refractive Surgery. Washington, DC, USA (2005):37905.
35. PRICE FW, TONON E, VANDENBURGH AM, STERN K, CHEETHAM JK, SCHIFFMAN RM: Safety and efficacy of reformulated ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. Presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology Fort Lauderdale, FL, USA (2003):2611.
36. ROBERTS CW: Comparison of the ocular comfort of acular ls with acular pf in healthy volunteers. Presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2004):4855.
37. FLACH AJ: Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans. Am. Ophthalmol. Soc. (2001) 99:205-210; discussion 210-212.
38. GAYNES BI, FISCELLA R: Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. (2002) 25:233-250.
39. CARONIA RM, PERRY HD, DONNENFELD ED: Antiinflammatory effect of preoperative ketorolac in phacoemulsification. J. Cataract Refract. Surg. (2002) 28:1880-1881.